LIST OF PROPOSED TOPICS FOR THE MONTHLY / BIMONTHLY MEETINGS:

TOPICS	DATE	SPEAKER
What is the ideal LDL target –		
Evidence and controversies		
glomerulonephritis (RPGN)		
Drugs to protect the kidney		
· · · · · · · · · · · · · · · · · · ·		
p, 5.6.68y		
The GLP analogue – Beyond		
diabetes		
Ambulatory BP measurement		
– What additional		
information is given by it		
_		
1		
its future impact		
Pharmacotherany and		
· · · · · · · · · · · · · · · · · · ·		
Selecting biologicals for the		
management of Asthma		
Interpreting the ENA profile		
Biologicals for the		
_		
· ·		
1		
vanoprazan		
Guidelines on ontimizing the		
1		
	What is the ideal LDL target – Evidence and controversies Inclisiran – when and why? Evaluation and treatment of rapidly progressive glomerulonephritis (RPGN) Drugs to protect the kidney GLP 1 – its role in normal physiology The GLP analogue – Beyond diabetes Ambulatory BP measurement – What additional information is given by it Work-up/ Management of resistant hypertension The epidemic of obesity and its future impact Pharmacotherapy and surgical management of obesity Evaluation of Severe Asthma Selecting biologicals for the management of Asthma Interpreting the ENA profile	What is the ideal LDL target — Evidence and controversies Inclisiran — when and why? Evaluation and treatment of rapidly progressive glomerulonephritis (RPGN) Drugs to protect the kidney GLP 1 — its role in normal physiology The GLP analogue — Beyond diabetes Ambulatory BP measurement — What additional information is given by it Work-up/ Management of resistant hypertension The epidemic of obesity and its future impact Pharmacotherapy and surgical management of obesity Evaluation of Severe Asthma Selecting biologicals for the management of Asthma Interpreting the ENA profile Biologicals for the management of RA/ ankylosing spondylitis/ sarcoidosis/ Lupus Potassium-competitive acid blocker (P-CAB) medications - Vanoprazan Guidelines on optimizing the use of proton pump

Oncology	Liquid biopsies in the management of cancers.	
	Newer drugs (based on the sponsors) in the management ofBreast/ oral/lung cancers/hematological cancers?	
Cardiology	Cardiologists role in managing complex structural heart conditions? Evaluation of cardiac risk in a patient walking into my clinic	